Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tonabersat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tonabersat overview

Tonabersat (HCB-1019) is under development for the treatment of diabetic macular edema (DME),Post-Acute Sequelae of COVID 2019 (PASC or Long COVID),  diabetic nephropathy (DR), dry and wet age-related macular degeneration (AMD) and geographic atrophy. It is administered through oral route in the form of tablet. It acts by targeting connexin 43 (Cx43) and NLRP3. 

It was also under development for the treatment of diabetic retinopathy (DR).

Inflammx Therapeutics overview

Inflammx Therapeutics is a provider of a biotechnology services. Inflammx Therapeutics is headquartered in Tampa, Florida, the US.

For a complete picture of Tonabersat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.